Contact
searchSearch
HMP Global
Login

Myelofibrosis

Myelofibrosis
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

John Mascarenhas, MD
Videos
JAK Inhibitors and Emerging Combination Strategies Advance Personalized Treatment in Myelofibrosis
10/24/2026
John Mascarenhas, MD
John Mascarenhas, MD, discusses advances in myelofibrosis treatment, highlighting individualized JAK inhibitor selection, emerging CALR-targeted therapies, novel combination strategies involving pelabresib and selinexor, and ongoing efforts...
John Mascarenhas, MD, discusses advances in myelofibrosis treatment, highlighting individualized JAK inhibitor selection, emerging CALR-targeted therapies, novel combination strategies involving pelabresib and selinexor, and ongoing efforts...
John Mascarenhas, MD, discusses...
10/24/2026
Oncology
Naseema Gangat, MBBS
Videos
Selcodebart Demonstrates Meaningful Anemia Responses in Patients With Myelofibrosis
09/23/2026
Naseema Gangat, MBBS
Naseema Gangat, MBBS, discusses results from the phase 2 RALLY-MF trial evaluating selcodebart for anemia in patients with myelofibrosis, highlighting durable hematologic responses across transfusion requirements, activity regardless of...
Naseema Gangat, MBBS, discusses results from the phase 2 RALLY-MF trial evaluating selcodebart for anemia in patients with myelofibrosis, highlighting durable hematologic responses across transfusion requirements, activity regardless of...
Naseema Gangat, MBBS, discusses...
09/23/2026
Oncology
Claire Harrison, MD
Videos
Frontline Selinexor Plus Ruxolitinib Improves Outcomes in Patients With Myelofibrosis
06/26/2026
Claire Harrison, MD
Claire Harrison, MD, discusses results from the phase 3 SENTRY trial showing that selinexor plus ruxolitinib significantly improved spleen responses and overall survival while demonstrating evidence of disease modification in patients with...
Claire Harrison, MD, discusses results from the phase 3 SENTRY trial showing that selinexor plus ruxolitinib significantly improved spleen responses and overall survival while demonstrating evidence of disease modification in patients with...
Claire Harrison, MD, discusses...
06/26/2026
Oncology
Claire Harrison, MD
Videos
First-in-Class Mutant CALR Antibody Demonstrates Durable Clinical Activity in Myelofibrosis
06/26/2026
Claire Harrison, MD
Claire Harrison, MD, discusses updated phase 1 data showing that the mutant CALR-targeted monoclonal antibody INCA033989 produced meaningful clinical and molecular responses with a favorable safety profile in patients with CALR-mutant...
Claire Harrison, MD, discusses updated phase 1 data showing that the mutant CALR-targeted monoclonal antibody INCA033989 produced meaningful clinical and molecular responses with a favorable safety profile in patients with CALR-mutant...
Claire Harrison, MD, discusses...
06/26/2026
Oncology
Prithviraj Bose, MD
Videos
Earlier Momelotinib Treatment Is Associated With Improved Outcomes in Patients WIth Myelofibrosis
06/23/2026
Prithviraj Bose, MD
Prithviraj Bose, MD, discusses post hoc analyses from the SIMPLIFY-1 and MOMENTUM trials showing that momelotinib provides meaningful spleen, symptom, and anemia benefits across myelofibrosis risk groups, with several outcomes appearing more...
Prithviraj Bose, MD, discusses post hoc analyses from the SIMPLIFY-1 and MOMENTUM trials showing that momelotinib provides meaningful spleen, symptom, and anemia benefits across myelofibrosis risk groups, with several outcomes appearing more...
Prithviraj Bose, MD, discusses...
06/23/2026
Oncology
Andrew Kuykendall, MD
Conference Coverage
Rusfertide Improves Hematocrit Control for Certain Patients With Myeloproliferative Neoplasms
06/03/2025
Andrew Kuykendall
Andrew Kuykendall, MD, discusses the results of the phase 3 VERIFY trial which compared rusfertide vs placebo for certain patients with myeloproliferative neoplasms.
Andrew Kuykendall, MD, discusses the results of the phase 3 VERIFY trial which compared rusfertide vs placebo for certain patients with myeloproliferative neoplasms.
Andrew Kuykendall, MD, discusses...
06/03/2025
Oncology
Daehyun Lee, MD
Conference Coverage
Pulmonary Hypertension Prevalent Among Patients With Myelofibrosis
06/03/2025
Daehyun Lee,  MD
Daehyun Lee, MD, discusses results from a retrospective cohort study which found that pulmonary hypertension is prevalent among patients with myelofibrosis and is associated with increased cardiovascular morbidity, including heart failure.
Daehyun Lee, MD, discusses results from a retrospective cohort study which found that pulmonary hypertension is prevalent among patients with myelofibrosis and is associated with increased cardiovascular morbidity, including heart failure.
Daehyun Lee, MD, discusses...
06/03/2025
Oncology
Lucía Pérez-Lamas, MD
Videos
Momelotinib Demonstrates Real-World Efficacy, Improved Anemia Symptoms Among Patients With Myelofibrosis
02/07/2025
Momelotinib for the treatment of myelofibrosis and anemia demonstrated improved real-world patient outcomes and a favorable safety profile, according to research presented at the 66th ASH Annual Meeting.
Momelotinib for the treatment of myelofibrosis and anemia demonstrated improved real-world patient outcomes and a favorable safety profile, according to research presented at the 66th ASH Annual Meeting.
Momelotinib for the treatment of...
02/07/2025
Oncology
John Mascarenhas, MD
Videos
Latest Updates in Navtemadlin Therapy for Patients With Myelofibrosis
01/29/2025
John Mascarenhas, MD
Navtemadlin therapy demonstrated efficacy and safety for patients with JAK inhibitor relapsed/refractory myelofibrosis, as well as improved biomarkers of disease burden, according to data presented by John Mascarenhas, MD.
Navtemadlin therapy demonstrated efficacy and safety for patients with JAK inhibitor relapsed/refractory myelofibrosis, as well as improved biomarkers of disease burden, according to data presented by John Mascarenhas, MD.
Navtemadlin therapy demonstrated...
01/29/2025
Oncology
Prithviraj Bose, MD
Videos
Zilurgisertib Alone or Combined With Ruxolitinib Well-Tolerated Among Patients With Myelofibrosis
07/25/2024
Prithviraj Bose, MD, shares results from an ongoing study that demonstrate that zilurgisertib as monotherapy or in combination with ruxolitinib had a favorable tolerance profile among patients with myelofibrosis.
Prithviraj Bose, MD, shares results from an ongoing study that demonstrate that zilurgisertib as monotherapy or in combination with ruxolitinib had a favorable tolerance profile among patients with myelofibrosis.
Prithviraj Bose, MD, shares...
07/25/2024
Oncology

Recent News

FDA Approval
FDA Approves Amivantamab and Hyaluronidase for Previously Treated Head and Neck Squamous Cell Carcinoma
11/06/2026
Stephanie Holland
Results from the phase 1b/2 OrigAMI-4 trial supported FDA accelerated approval of subcutaneous amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck squamous cell carcinoma, introducing a dual...
Results from the phase 1b/2 OrigAMI-4 trial supported FDA accelerated approval of subcutaneous amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck squamous cell carcinoma, introducing a dual...
Results from the phase 1b/2...
11/06/2026
Oncology
News
Varegacestat Advances Toward European Approval for Desmoid Tumors Following RINGSIDE Survival Benefit
11/05/2026
Emily Estrada
Based on results from the phase 3 RINGSIDE trial, the European Medicines Agency has validated the marketing authorization application for varegacestat in adults with desmoid tumors, following significant improvements in progression-free...
Based on results from the phase 3 RINGSIDE trial, the European Medicines Agency has validated the marketing authorization application for varegacestat in adults with desmoid tumors, following significant improvements in progression-free...
Based on results from the phase...
11/05/2026
Oncology
News
Lirafugratinib Receives NCCN Category 2A Recommendation Following FDA Approval in FGFR2-Altered Cholangiocarcinoma
11/05/2026
Emily Estrada
Following FDA approval supported by the phase 1/2 ReFocus trial, lirafugratinib has been added to the NCCN Guidelines as a Category 2A preferred subsequent-line treatment option for patients with cholangiocarcinoma harboring FGFR2 fusions or...
Following FDA approval supported by the phase 1/2 ReFocus trial, lirafugratinib has been added to the NCCN Guidelines as a Category 2A preferred subsequent-line treatment option for patients with cholangiocarcinoma harboring FGFR2 fusions or...
Following FDA approval supported...
11/05/2026
Oncology
News
Pumitamig Plus Chemotherapy Shows Antitumor Activity Regardless of Brain Metastasis Status
11/04/2026
Emily Estrada
Results from two phase 2 trials demonstrated encouraging intracranial responses with pumitamig plus chemotherapy in patients with small cell lung cancer and triple-negative breast cancer with brain metastases, supporting further investigation...
Results from two phase 2 trials demonstrated encouraging intracranial responses with pumitamig plus chemotherapy in patients with small cell lung cancer and triple-negative breast cancer with brain metastases, supporting further investigation...
Results from two phase 2 trials...
11/04/2026
Oncology
News
SEZ6-Targeted Antibody-Drug Conjugate ABBV-706 Demonstrates Promising Antitumor Activity in Relapsed or Refractory Small Cell Lung Cancer
11/04/2026
Emily Estrada
Updated phase 1 results demonstrated promising antitumor activity with the SEZ6-targeted antibody-drug conjugate ABBV-706 in relapsed or refractory small cell lung cancer, with encouraging response and survival outcomes alongside exploratory...
Updated phase 1 results demonstrated promising antitumor activity with the SEZ6-targeted antibody-drug conjugate ABBV-706 in relapsed or refractory small cell lung cancer, with encouraging response and survival outcomes alongside exploratory...
Updated phase 1 results...
11/04/2026
Oncology
News
Phase 1 Trial Shows 70% Response Rate With SKB500 in Heavily Pretreated Patients With Small Cell Lung Cancer
11/04/2026
Emily Estrada
Updated results from a phase 1 trial demonstrated promising antitumor activity with the B7-H3-directed antibody-drug conjugate SKB500 in heavily pretreated patients with small cell lung cancer, with the lower dose showing more favorable...
Updated results from a phase 1 trial demonstrated promising antitumor activity with the B7-H3-directed antibody-drug conjugate SKB500 in heavily pretreated patients with small cell lung cancer, with the lower dose showing more favorable...
Updated results from a phase 1...
11/04/2026
Oncology
News
Varegacestat Significantly Improves Pain, Physical Function, and Quality of Life in Patients With Desmoid Tumors
11/04/2026
Emily Estrada
Results from RINGSIDE trial demonstrated rapid and sustained improvements in patient-reported pain, desmoid-related symptoms, physical function, and quality of life with varegacestat compared with placebo in patients with progressing desmoid...
Results from RINGSIDE trial demonstrated rapid and sustained improvements in patient-reported pain, desmoid-related symptoms, physical function, and quality of life with varegacestat compared with placebo in patients with progressing desmoid...
Results from RINGSIDE trial...
11/04/2026
Oncology
FDA Alerts
Zanubrutinib Combination Receives FDA Priority Review Following Positive Phase 3 MANGROVE Results
11/04/2026
Stephanie Holland
Results from the phase 3 MANGROVE trial supported FDA Priority Review of zanubrutinib plus rituximab for previously untreated mantle cell lymphoma, following a significant progression-free survival benefit compared with bendamustine plus...
Results from the phase 3 MANGROVE trial supported FDA Priority Review of zanubrutinib plus rituximab for previously untreated mantle cell lymphoma, following a significant progression-free survival benefit compared with bendamustine plus...
Results from the phase 3...
11/04/2026
Oncology
News
Medicare Expands Coverage of Signatera MRD Testing for Hepatocellular Carcinoma Surveillance
11/03/2026
Stephanie Holland
Medicare coverage has been extended to serial Signatera molecular residual disease testing for surveillance of patients with early-stage hepatocellular carcinoma who have no evidence of disease following surgery, supported by real-world...
Medicare coverage has been extended to serial Signatera molecular residual disease testing for surveillance of patients with early-stage hepatocellular carcinoma who have no evidence of disease following surgery, supported by real-world...
Medicare coverage has been...
11/03/2026
Oncology
News
What to Expect at the 2026 NANETS Multidisciplinary NET Medical Symposium
11/02/2026
Janelle Bradley
The 2026 NANETS Multidisciplinary NET Medical Symposium will spotlight emerging research, evolving treatment strategies, and practical insights to advance neuroendocrine tumor care.
The 2026 NANETS Multidisciplinary NET Medical Symposium will spotlight emerging research, evolving treatment strategies, and practical insights to advance neuroendocrine tumor care.
The 2026 NANETS...
11/02/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use